Study of DR-0202 for advanced solid tumors after multiple treatments
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancers: breast (triple-negative or HR+/HER2-), non-small cell lung, cervical, prostate, pancreatic, head and neck, endometrial, ovarian, stomach/esophageal, or bladder that has spread or cannot be removed.
- Your cancer must have returned or not responded to at least two prior treatments, and no standard options are left.
- Your tumor must be measurable on scans.
- You must be able to care for yourself (ECOG 0 or 1).
- You must have adequate bone marrow, kidney, and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, DRP-104, for people with advanced non-small cell lung cancer that has a change in the NFE2L2 or KEAP1 genes. It is for people whose cancer has gotten worse after standard treatments like chemotherapy and immunotherapy.
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This trial tests a new drug called DR30206 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how the body processes it.
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.